24 / 40
Tripletes
1. CRC treatment continuum representation based on: Van Cutsem E, et al. Ann Oncol 2016;27:1386‒422. 2. Study sponsor: AIO-Studien-gGmbH.ClinicalTrials.gov identifier:
NCT01328171 (accessed 8-03-2018); Geissler M, et al. Ann Oncol 2017;28(Suppl 5):abstract 475O (and oral presentation). 3. Study sponsor: UNICANCER. ClinicalTrials.gov
identifier: NCT02980510 (accessed 8-03-2018. 4. Study sponsor: Gruppo Oncologico del Nord-Ovest (GONO). Clinicaltrials.gov identifier NCT03231722 (accessed 8-03-2018).
VOLFI: NCT01328171
2
PANIRINOX: NCT02980510
4
TRIPLETE: NCT03231722
3
mCRC Unresectable
WT
RAS
(n = 96)
R
Treatment until PD, resectable status
or to maximum 12 cycles
mFOLFOXIRI
†
Q2W+
panitumumab 6 mg/kg
Q2W (n = 63)
FOLFOXIRI
‡
Q2W
(n = 33)
2:1
If resectable:
Surgery then protocol
treatment (max 12 cycles)
If CR/PR/SD after 12 cycles:
re-induction with
same combination
recommended on PD
Unresectable mCRC
WT
RAS
/WT
BRAF
(N ~ 432)
mFOLFOXIRI
†
Q2W
+ panitumumab
6 mg/kg Q2W
mFOLFOX6 Q2W +
panitumumab
6 mg/kg Q2W
R
Treatment to maximum 12 cycles
If no PD: patients will receive
maintenance 5FU/LV + panitumumab
‡
until PD, unacceptable toxicity or
patient’s refusal
Unresectable Mcrc WT
RAS
/WT
BRAF
(N = 209)
FOLFIRINOX
†
+ panitumumab Q2W
mFOLFOX6 + panitumumab Q2W
R
ccfDNA analysis